JPWO2022006397A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022006397A5 JPWO2022006397A5 JP2023524492A JP2023524492A JPWO2022006397A5 JP WO2022006397 A5 JPWO2022006397 A5 JP WO2022006397A5 JP 2023524492 A JP2023524492 A JP 2023524492A JP 2023524492 A JP2023524492 A JP 2023524492A JP WO2022006397 A5 JPWO2022006397 A5 JP WO2022006397A5
- Authority
- JP
- Japan
- Prior art keywords
- aspartic acid
- molar ratio
- ranges
- isoleucine
- serine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000003704 aspartic acid Nutrition 0.000 claims 309
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 308
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 308
- 229960000310 isoleucine Drugs 0.000 claims 80
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 80
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 79
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 76
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 68
- 239000004473 Threonine Substances 0.000 claims 68
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 68
- 239000004474 valine Substances 0.000 claims 68
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 67
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 42
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 42
- 238000009472 formulation Methods 0.000 claims 40
- 239000000203 mixture Substances 0.000 claims 40
- 229940024606 amino acid Drugs 0.000 claims 33
- 235000001014 amino acid Nutrition 0.000 claims 33
- 150000001413 amino acids Chemical class 0.000 claims 33
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 9
- 230000001225 therapeutic effect Effects 0.000 claims 9
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 230000001737 promoting effect Effects 0.000 claims 8
- 230000036571 hydration Effects 0.000 claims 6
- 238000006703 hydration reaction Methods 0.000 claims 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 6
- 230000007358 intestinal barrier function Effects 0.000 claims 5
- 239000004471 Glycine Substances 0.000 claims 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 4
- 239000004472 Lysine Substances 0.000 claims 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 4
- 230000018044 dehydration Effects 0.000 claims 4
- 238000006297 dehydration reaction Methods 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 238000010521 absorption reaction Methods 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 239000000872 buffer Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000003792 electrolyte Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 235000013361 beverage Nutrition 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000005027 intestinal barrier Anatomy 0.000 claims 2
- -1 use Substances 0.000 claims 2
- 102000000905 Cadherin Human genes 0.000 claims 1
- 108050007957 Cadherin Proteins 0.000 claims 1
- 102000004056 Claudin-2 Human genes 0.000 claims 1
- 108090000580 Claudin-2 Proteins 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 150000008575 L-amino acids Chemical class 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102000003940 Occludin Human genes 0.000 claims 1
- 108090000304 Occludin Proteins 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 150000001510 aspartic acids Chemical class 0.000 claims 1
- 230000003870 intestinal permeability Effects 0.000 claims 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063047300P | 2020-07-02 | 2020-07-02 | |
| US63/047,300 | 2020-07-02 | ||
| PCT/US2021/040090 WO2022006397A1 (en) | 2020-07-02 | 2021-07-01 | Formulations for promoting hydration and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023533617A JP2023533617A (ja) | 2023-08-03 |
| JP2023533617A5 JP2023533617A5 (https=) | 2024-07-08 |
| JPWO2022006397A5 true JPWO2022006397A5 (https=) | 2024-07-08 |
Family
ID=79314908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023524492A Pending JP2023533617A (ja) | 2020-07-02 | 2021-07-01 | 水分補給を促進するための製剤およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12357600B2 (https=) |
| EP (1) | EP4175662A4 (https=) |
| JP (1) | JP2023533617A (https=) |
| KR (1) | KR20230047371A (https=) |
| CN (1) | CN116194136A (https=) |
| AU (1) | AU2021300188A1 (https=) |
| BR (1) | BR112022027124A2 (https=) |
| CA (1) | CA3184691A1 (https=) |
| IL (1) | IL299488A (https=) |
| MX (1) | MX2023000004A (https=) |
| WO (1) | WO2022006397A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11878073B1 (en) * | 2022-09-20 | 2024-01-23 | Entrinsic, LLC | Generation of hydration-targeted formulations and methods of use therein |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3916903A1 (de) * | 1989-05-24 | 1991-02-28 | Leopold Pharma Gmbh | Waessrige zusammensetzung fuer die parenterale ernaehrung |
| JP2002275059A (ja) * | 2001-03-15 | 2002-09-25 | Inst Of Physical & Chemical Res | 腎機能障害改善用アミノ酸組成物 |
| WO2010017403A2 (en) * | 2008-08-06 | 2010-02-11 | Immunopath Profile, Inc. | Therapeutic compositions, devices and methods for observing treated tissues |
| CN102170876B (zh) * | 2008-10-06 | 2013-12-04 | 株式会社明治 | 含有氨基酸组合物作为有效成分的耐力提高剂、抗疲劳剂或疲劳恢复剂 |
| KR101758424B1 (ko) * | 2010-09-24 | 2017-07-14 | 유니버시티 오브 플로리다 리서치 파운데이션, 인크. | 위장 기능을 증진시키기 위한 물질 및 방법 |
| HK1204290A1 (en) * | 2012-02-08 | 2015-11-13 | University Of Florida Research Foundation, Inc. | Materials and methods for treating diarrhea |
| EP3459540A1 (en) * | 2014-11-24 | 2019-03-27 | Entrinsic Health Solutions, Inc. | Amino acid compositions for the treatment of symptoms of disease |
| EP3522882A4 (en) * | 2016-10-04 | 2020-06-24 | The University of Florida Research Foundation Incorporated | AMINO ACID COMPOSITIONS AND USES THEREOF |
| CN109218470B (zh) * | 2017-07-05 | 2021-08-24 | 中兴通讯股份有限公司 | 移动终端及其控制方法 |
| WO2019070753A1 (en) * | 2017-10-02 | 2019-04-11 | University Of Florida Research Foundation, Incorporated | AMINO ACID COMPOSITIONS AND METHODS FOR TREATING DIARRHEA |
-
2021
- 2021-07-01 IL IL299488A patent/IL299488A/en unknown
- 2021-07-01 EP EP21834528.8A patent/EP4175662A4/en active Pending
- 2021-07-01 CA CA3184691A patent/CA3184691A1/en active Pending
- 2021-07-01 CN CN202180056268.5A patent/CN116194136A/zh active Pending
- 2021-07-01 AU AU2021300188A patent/AU2021300188A1/en active Pending
- 2021-07-01 MX MX2023000004A patent/MX2023000004A/es unknown
- 2021-07-01 JP JP2023524492A patent/JP2023533617A/ja active Pending
- 2021-07-01 BR BR112022027124A patent/BR112022027124A2/pt unknown
- 2021-07-01 WO PCT/US2021/040090 patent/WO2022006397A1/en not_active Ceased
- 2021-07-01 KR KR1020237003742A patent/KR20230047371A/ko active Pending
-
2022
- 2022-12-30 US US18/148,903 patent/US12357600B2/en active Active
-
2025
- 2025-06-10 US US19/233,780 patent/US20250367154A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2426485T3 (es) | Composiciones farmacéuticas que comprenden hGH para administración oral | |
| ES2932498T3 (es) | Composiciones que comprenden el péptido WKDEAGKPLVK | |
| US12161614B2 (en) | Amino acid compositions for the amelioration of symptoms of environmental enteropathy | |
| US10471142B2 (en) | Combination therapy using immunoglobulin and C1-Inhibitor | |
| RU2008136324A (ru) | Желудочно-кишечный пролиферативный фактор и его применения | |
| ES3031633T3 (en) | Annexin a1 n-terminal peptide formulations and methods | |
| ES2922551T3 (es) | Tratamiento de pacientes con diabetes mellitus tipo 2 | |
| Luyten et al. | Yellow nail syndrome and onychomycosis: experience with itraconazole pulse therapy combined with vitamin E | |
| JP5403935B2 (ja) | 経口用の慢性疼痛予防または治療剤 | |
| US20080095837A1 (en) | Human growth hormone formulations | |
| ES2547379T3 (es) | Utilización de calcitonina para el tratamiento de la AR | |
| WO2014170811A2 (en) | Novel mutant l-asparaginases | |
| JP2009242366A (ja) | 持続性解熱鎮痛消炎剤 | |
| JP5865903B2 (ja) | 経口鉄欠乏療法 | |
| JPWO2022006397A5 (https=) | ||
| JP2021506907A5 (https=) | ||
| ES2612584T3 (es) | Piroxicam para el tratamiento profiláctico y terapéutico de infecciones por herpes | |
| WO2022019742A1 (es) | Paquete farmaceutico para prevención y/o tratamiento de enfermedad por covid-19 y uso del mismo | |
| KR20090103656A (ko) | 섬유근육통 치료제 | |
| CN1610558A (zh) | 用于治疗钙化的含阿司匹林的透皮吸收药物组合物 | |
| JP2008542430A (ja) | 安定化ｉｌ−２１組成物 | |
| CN102264375A (zh) | 用于预防或治疗糖尿病多发性周围神经病变的小牛血去蛋白制剂 | |
| KR20180122144A (ko) | 인슐린 비강 전달용 제제 | |
| EA011489B1 (ru) | Средство для лечения простудных заболеваний |